Deanol and physostigmine in the treatment of L-dopa-induced dyskinesias.

Abstract

Deanol and placebo were administered to 10 parkinsonian patients with levodopa-induced dyskinesias in a double-blind, crossover fashion. Deanol and placebo did not differ significantly in their effects on dyskinesias. The reported properties of deanol seem to be attributable to a placebo effect. There was no correlation with the results of the physostigmine test. Despite these disappointing results deanol remains intriguing, because in individual cases remarkable improvements on dyskinesias are reported.

• Authors: S F Lindeboom, J P Lakke
• Journal: Acta neurologica Scandinavica (Acta Neurol Scand) Vol. 58 Issue 2 Pg. 134-8 (Aug 1978) ISSN: 0001-6314 [Print] Denmark
• PMID: 360761 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Ethanolamines
• Placebos
• Deanol
• Levodopa
• Physostigmine

Topics

• Aged
• Clinical Trials as Topic
• Deanol (therapeutic use)
• Double-Blind Method
• Drug Evaluation
• Dyskinesia, Drug-Induced (drug therapy)
• Ethanolamines (therapeutic use)
• Female
• Humans
• Levodopa (adverse effects, therapeutic use)
• Male
• Middle Aged
• Parkinson Disease (drug therapy)
• Physostigmine (therapeutic use)
• Placebos